Invention:
This technology provides a mixture of estrogens that are selective for ER-β activation, offering a novel treatment for neurological and psychological disorders.
Background:
Mental disorders are the number one contributor to non-communicable diseases worldwide. Mental disorders such as schizophrenia, mood disorders, substance abuse and dementia contribute more to global disease burden than cancer or cardiovascular diseases. Thus, there is a great need for novel therapeutics that can address these devastating mental disorders.
Advantages:
- Enhances cognition
- Reduces anxiety
- Decreases depressive-like behaviors
- Inhibits neuroendocrine responses to stress
- Mitigates inflammatory responses (e.g. multiple sclerosis)
- Reduces aggression
Applications:
- In preclinical studies, selective ER-β activation that positively impacts a variety of neurological and psychological disorders
- Lead to developments on current mental therapeutics
